The pro forma equity value of the portion of the combined company attributable to Tevogen Bio Inc (“Tevogen Bio”) stockholders is an expected $1.2 billion. Tevogen Bio is an advanced-stage specialty ...
New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW), a publicly-traded special purpose acquisition company, today announced ...
New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the ...
Immunotherapy developer Tevogen (TVGN) plans to go public through a merger with SPAC Semper Paratus Acquisition Corp. (NASDAQ:LGST), with the deal estimating the enterprise value of the combined ...
New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq: LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced ...
SPAC Semper Paratus Acquisition Corp. (NASDAQ:LGST) shareholders have approved a planned merger with immunotherapy developer Tevogen Bio (TVGN). Semper said in a statement issued Thursday that it was ...
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Inc. (“Tevogen Bio”) is pleased to announce the appointment of safety management expert Victor Sordillo, PE, CSP, M.B.A., to its Board of Directors. Mr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback